COVID-Flu Combination Vaccine Approval Expands mRNA
Quick Facts
What Is mCombriax and Why Does This Approval Matter?
mCombriax represents a practical shift in respiratory virus prevention: one injection targets two infections that often circulate during the same season and can be especially dangerous for older adults. EMA says the vaccine is intended for people aged 50 years and older and contains messenger RNA instructions for immune targets from SARS-CoV-2 and seasonal influenza viruses.
The public health importance is not only convenience. Influenza and COVID-19 can each lead to hospitalization, pneumonia, worsening heart or lung disease, and death in higher-risk groups. EMA noted that co-infection with influenza virus and SARS-CoV-2 can cause more severe disease than either infection alone, making combined protection an important area for vaccine development.
How Does a Combined COVID-Flu mRNA Vaccine Work?
According to EMA's medicine overview, mCombriax does not contain influenza virus or SARS-CoV-2 and cannot cause flu or COVID-19. After injection into the upper arm, cells briefly produce selected viral proteins, prompting antibodies and T-cell responses that may help the body respond faster if exposed later.
The influenza component targets major seasonal flu groups, including influenza A H1N1, influenza A H3N2, and influenza B Victoria lineage. Like other seasonal respiratory vaccines, the product's composition is expected to need periodic updating as circulating influenza strains and SARS-CoV-2 variants change.
What Did Regulators Find About Safety and Immune Response?
EMA's assessment cited a main study involving more than 8,000 adults aged 50 and older. Participants receiving mCombriax developed antibody levels against influenza and SARS-CoV-2 that were comparable to those seen after receiving Spikevax with either Fluzone HD or Fluarix, two authorized influenza vaccine options.
The most common side effects reported by EMA included injection-site pain, tiredness, muscle pain, joint pain, headache, chills, swollen lymph nodes, nausea, vomiting, and fever. Regulators described these reactions as generally mild and short-lived, while also noting that national public health authorities will decide how the vaccine fits into seasonal vaccination programs.
Frequently Asked Questions
No. EMA lists mCombriax as authorized only for adults aged 50 years and older.
It may be an option where national health authorities recommend it, but vaccine choice depends on local guidance, availability, age, medical risk, and individual clinical advice.
No. EMA states that mCombriax does not contain the viruses themselves and cannot cause influenza or COVID-19.
References
- European Medicines Agency. First combined COVID-19 and influenza vaccine for people 50 years and older. February 27, 2026.
- European Medicines Agency. mCombriax EPAR - Medicine overview. First published April 30, 2026.
- European Centre for Disease Prevention and Control. Factsheet about seasonal influenza.
- World Health Organization. WHO COVID-19 dashboard.